Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2023; 77(2): 147–153. doi: 10.48095/ccgh2023147.

Kulatý stůl: Subkutánní infliximab v léčbě IBD a terapeutické monitorování hladin léčiva v praxi

Karin Černá 1

+ Affiliation

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Schreiber S, Ben-Horin S, Leszczyszyn J et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 2021; 160(7): 2340–2353. doi: 10.1053/ j.gastro.2021.02.068.
2. Kim H, Alten R, Cummings F et al. Innovative approaches to biologic development on the trail of CT-P13: Biosimilars, value-added medicines, and biobetters. MAbs 2021; 13: 1868078. doi: 10.1080/19420862.2020.1868078.
3. Little RD, Ward MG, Wright E et al. Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease – Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics. J Clin Med 2022; 11(20): 6173. doi: 10.3390/jcm11206173.
4. Hanzel J, Bukkems LH, Gecse KB et al. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 2021; 54(10): 1309–1319. doi: 10.1111/apt.16609.
5. Hanzel J, Jansen JM, Ter Steege RW et al. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. Inflamm Bowel Dis 2022; 28(4): 495–501. doi: 10.1093/ibd/izab099.
6. Summary of Product Characteristics. 2023 [online]. Dostupné z: https: //www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf.
7. Buisson A, Nachury M, Reymond M et al. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH study. Clin Gastroenterol Hepatol 2022: S1542–3565(22)00776-5. doi: 10.1016/j.cgh.2022.08.011.
8. Smith PJ, Critchley L, Storey D et al. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. J Crohns Colitis 2022; 16(9): 1436–1446. doi: 10.1093/ecco-jcc/jjac053.
9. Casteele, N.V.; Gils, A. Editorial: Variability in adalimumab trough and peak serum concentrations. Aliment. Pharmacol. Ther 2017; 45, 1475–1476. doi: 10.1111/apt.14049.
10. Srinivasan A, Vasudevan A, McFarlane A et al. Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn’s Disease. J Crohns Colitis 2018; 12(3): 280–288. doi: 10.1093/ecco-jcc/jjx144.
11. Alten R, An Y, Kim DH et al. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. Clin Drug Investig 2022; 42(6): 477–489. doi: 10.1007/s40261-022-01162-6.
12. Roblin X, Veyrard P, Bastide L et al. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn’s disease. Aliment Pharmacol Ther 2022; 56(1): 77–83. doi: 10.1111/apt.16852.
13. Huguet JM, García-Lorenzo V, Martí L et al. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines 2022; 10(9): 2130. doi: 10.3390/biomedicines10092130.
14. Wang Z, Verstockt B, Sabino J et al. Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study. Clin Gastroenterol Hepatol 2023; S1542–3565(23)00034-4. doi: 10.1016/j.cgh.2023.01.004.
15. D‘Haens G. Anti-TNF treatment in Crohn’s disease: toward tailored therapy? Am J Gastroenterol 2010; 105(5): 1140–1141. doi: 10.1038/ajg.2010.15.
16. Yarur AJ, Kanagala V, Stein DJ et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn‘s disease. Aliment Pharmacol Ther 2017; 45(7): 933–940. doi: 10.1111/apt.13970.
17. Gu B, Venkatesh K, Williams AJ et al. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease. World J Gastroenterol 2022; 28(23): 2597–2608. doi: 10.3748/wjg.v28.i23.2597.
18. Reinhold I, Blümel S, Schreiner J et al. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflamm Intest Dis 2021; 6(1): 38–47. doi: 10.1159/000511296.
19. Schreiber S, Jang BI, Borzan V et al. Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn’s Disease. Gastroenterology 2018; 154: 1371.
20. Ye BD, Leszczyszyn J, Dudkowiak R et al. Exposure-response relationship of subcutaneous infliximab (CT-P13 SC) in patients with active Crohn’s disease and ulcerative colitis: Analysis from a multicenter, randomized controlled pivotal trial. United Eur Gastroenterol Week 2020; 8(S1): 385–386.
21. Dubinsky MC, Mendiolaza M, Phan BL et al. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity. Inflamm Bowel Dis 2022; 28(9): 1375–1385. doi: 10.1093/ibd/izab285.
22. Fasanmade AA, Adedokun OJ, Blank M et al. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: A retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011; 33(7): 946–964. doi: 10.1016/j.clinthera.2011.06.002.
23. Dotan I, Ron Y, Yanai H et al. Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study. Inflamm. Bowel Dis 2014; 20(12): 2247–2259. doi: 10.1097/MIB.0000000000000212.
24. Smith PJ, Critchley L, Storey D et al. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab (Ct-P13): A Multi-Centre Cohort Study. J Crohn’s Colitis 2022; 16(8): 1436–1446. doi: 10.1093/ecco-jcc/jjac053.
25. Malissen B, Tamoutounour S, Henri S. The origins and functions of dendritic cells and macrophages in the skin. Nat Rev Immunol 2014; 14(6): 417–428. doi: 10.1038/nri3683.
26. Kim H, Alten R, Cummings F et al. Innovative approaches to biologic development on the trail of CT-P13: Biosimilars, value-added medicines, and biobetters. MAbs. 2021; 13(1): 1868078. doi: 10.1080/19420862.2020.1868078.
27. Bar-Yoseph H, Pressman S, Blatt A et al. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies. Gastroenterology 2019; 157(5): 1338–1351. doi: 10.1053/ j.gastro.2019.08.009.
28. van Schie KA, Hart MH, de Groot ER et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015; 74(8): 311–314. doi: 10.1136/ annrheumdis-2015-207529.
29. Buurman DJ, Maurer JM, Keizer RJ et al. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther 2015; 42(5): 529–539. doi: 10.1111/apt.13299.
30. Van Stappen T, Vande Casteele N, Van Assche G et al. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut 2018; 67(5): 818–826. doi: 10.1136/gutjnl-2016-313071.
31. Bloem K, van Leeuwen A, Verbeek G et al. Systematic comparison of drug-tolerant asasin for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients. J Immunol Methods 2015; 418: 29–38. doi: 10.1016/ j.jim.2015.01.007.
32. Kharlamova N, Hermanrud C, Dunn N et al. Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier. Front Immunol 2020; 11: 1365. doi: 10.3389/fimmu.2020.01365.
33. Rinaudo-Gaujous M, Roblin X, Marotte H et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015; 74(8): e40. doi: 10.1136/annrheumdis-2015-207503.
34. Hock BD, McKenzie JL, Goddard L et al. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab – and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay. Ther Drug Monit 2018; 40(6): 705–715. doi: 10.1097/FTD.0000 000000000553.
35. Weisshof R, Ungar B, Blatt A et al. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay. Inflamm Bowel Dis 2016; 22(7): 1655–1661. doi: 10.1097/MIB.0000000000000797.

Credited self-teaching test